Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketotifen in Primary PCI Patients With STEMI
NCT05511831Phase 4Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of ketotifen in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Myocardial Infarct Size at 3 months. Status: unknown.
02
Drugs
ketotifen
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05511831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511831.